Provided by Tiger Trade Technology Pte. Ltd.

Denali Therapeutics Inc.

19.53
-0.5350-2.67%
Volume:655.91K
Turnover:12.77M
Market Cap:3.10B
PE:-6.57
High:20.09
Open:19.85
Low:18.95
Close:20.06
52wk High:23.77
52wk Low:10.57
Shares:158.59M
Float Shares:144.00M
Volume Ratio:0.80
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9700
EPS(LYR):-2.9700
ROE:-45.69%
ROA:-27.56%
PB:3.05
PE(LYR):-6.57

Loading ...

Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says

MT Newswires Live
·
Nov 18, 2025

Can Denali Therapeutics (DNLI)’s New Leadership Steady the Narrative Amid Mounting Losses?

Simply Wall St.
·
Nov 16, 2025

Stock Track | Denali Therapeutics Soars 5.33% Pre-Market on Oppenheimer's Buy Rating

Stock Track
·
Nov 10, 2025

Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

TIPRANKS
·
Nov 10, 2025

Denali Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Timothy Van Hauwermeiren

Reuters
·
Nov 07, 2025

Denali Therapeutics Q3 net loss widens to $126.9 mln

Reuters
·
Nov 07, 2025

Denali Therapeutics reports third quarter net loss of $126.9 million

Reuters
·
Nov 07, 2025

BRIEF-Denali Therapeutics Q3 Operating Expenses USD 137.434 Million

Reuters
·
Nov 07, 2025

Denali Therapeutics Appoints Tim Van Hauwermeiren to Board and Names Peter Chin Acting Chief Medical Officer

Reuters
·
Nov 07, 2025

Press Release: Denali Therapeutics Announces Board and Executive Leadership Updates

Dow Jones
·
Nov 07, 2025

Denali Therapeutics (DNLI) Gets a Buy from J.P. Morgan

TIPRANKS
·
Nov 05, 2025

U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx, Cardinal Health

Reuters
·
Nov 04, 2025

Denali Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview

Reuters
·
Nov 01, 2025

Wedbush Keeps Their Buy Rating on Denali Therapeutics (DNLI)

TIPRANKS
·
Oct 14, 2025

Denali Therapeutics announces FDA extension of tividenofusp BLA review timeline

TIPRANKS
·
Oct 14, 2025

Denali Therapeutics Announces FDA Review Extension for Tividenofusp Alfa in Hunter Syndrome; New PDUFA Date Set for April 2026

Reuters
·
Oct 14, 2025

Denali Therapeutics Inc - Pdufa Date Extended to April 5, 2026

THOMSON REUTERS
·
Oct 14, 2025

Denali Therapeutics Announces FDA Review Extension of Bla for Tividenofusp Alfa for the Treatment of Mps Ii (Hunter Syndrome)

THOMSON REUTERS
·
Oct 14, 2025

Denali Therapeutics Inc: Believes Updated Information Submitted in Amendment Does Not Affect Clinical Pharmacology or Benefit-Risk Conclusions of Bla

THOMSON REUTERS
·
Oct 14, 2025

Denali Therapeutics Inc: No Additional Data Were Requested by FDA in Ma Letter

THOMSON REUTERS
·
Oct 14, 2025